Advanced Blood-Brain Barrier Drug Delivery

doi:10.3390/books978-3-0365-6416-6

Download Url(s)

https://mdpi.com/books/pdfview/book/6675

Contributor(s)

Pardridge, William M. (editor)

Language

English

Show full item record

Abstract

Advanced Blood-Brain Barrier Drug Delivery is a reprint with a summary editorial, followed by 16 chapters that cover five areas of brain drug delivery, including receptor-mediated transport (RMT), carrier-mediated transport (CMT), active efflux transport (AET), Trojan horse lipid nanoparticles (LNP), and in vivo methods for measurement of drug transport across the blood–brain barrier (BBB).

URI

https://directory.doabooks.org/handle/20.500.12854/96729

Keywords

blood–brain barrier (BBB); brain drug delivery; prodrugs; solute carriers (SLCs); lysosomal storage disease; neuronopathic mucopolysaccharidosis; blood–brain barrier; neurodegeneration; enzyme replacement therapy; receptor-mediated transcytosis; transferrin receptor; insulin receptor; endothelium; receptor-mediated transport; carrier-mediated transport; genetic engineering; IgG fusion proteins; nanoparticles; liposomes; TrkB; agonist antibody; variable new antigen receptor (VNAR); neuroprotection; transferrin receptor 1 (TfR1); blood-brain barrier (BBB); 6-OHDA; Parkinson’s disease; bispecific antibody; alpha-synuclein (αSYN); Parkinson’s disease (PD); immunotherapy; monoclonal antibody; transferrin receptor (TfR); receptor-mediated transcytosis (RMT); single domains antibody; IGF1R; neurotensin; protein-based therapy; lysosomal storage disorders; fusion proteins; Alzheimer’s disease; neurotrophic factors; decoy receptors; ATP-binding cassette transporters; drug delivery; ischemic stroke; SLC transporters; lipid nanoparticle; ssPalm; mRNA transfection; hCMEC/D3 cells; cell toxicity; SWATH-MS; translation; chaperonin-containing TCP-1; proton-coupled organic cation antiporter; photo-affinity labeling; proteomics; SWATH-MS (sequential window acquisition of all theoretical-mass spectra); pharmacokinetics; compartmental models; physiologically based PK models; blood-brain barrier; antibody; cavernous sinus; BBB–peptide shuttle; brain delivery; solute carrier (SLC) transporters; amyotrophic lateral sclerosis (ALS); NSC-34 cell lines; taurine transporter (Taut); large amino acid transporter 1 (LAT1); monocarboxylate transporters (MCTs); organic cation transporters (OCTNs); choline transporter-like protein-1 (CTL1); TNF-α inhibitor; molecular Trojan horse; endosomal; liposome; nanoparticle; targeting; transferrin; n/a